Henry Schein to market video game-like dementia screening tool

an old man without a smile
The Cognivue device presents visual stimuli to patients and summarizes their results in a single-page report stored in the cloud.

Cerebral Assessment Systems (CAS) tapped Henry Schein to market its screening device that uses cognitive assessment to detect early signs of dementia.

The device, dubbed Cognivue, snagged a de novo clearance from the FDA in 2015. It displays visual stimuli on a computer screen and monitors and measures how the brain processes information, according to a statement. The test is personalized to each patient; the level of difficulty depends on how well a patient’s brain is performing.

Cognivue presents test results in a report that is stored in the cloud. It provides physicians with a single quantitative score for brain health so they can investigate potential issues before they escalate.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

RELATED: New York startup trots out video game-like screening device for Alzheimer's

“With Henry Schein Medical, our goal is to distribute the device to all the practitioners looking for a solution that makes the assessment of cognitive function as routine as having your blood pressure taken,” said Charles Duffy, M.D., who created the Cognivue device, in the statement. “Although an early diagnosis does not solve the cure, minimizing the toll dementia takes on patients—by addressing some of the potential causes associated with this condition—is the next best option."

Boston’s Akili Interactive Labs is developing a similar platform for the detection of Alzheimer’s disease. The startup joined forces with Pfizer in 2014 to investigate whether its video game-based platform really could differentiate between patients with Alzheimer’s and without. Last December, the duo presented data showing that its proprietary video game platform could tell the difference between patients who had brain amyloidosis—measured by PET scan—and patients without amyloidosis.

In a different tack, Alzeca Biosciences, which recently raised $11 million in series A financing, is working on a nanoparticle contrast agent for MRI. The agent is designed for the early detection of Alzheimer’s and other neurodegenerative disorders. While PET imaging is used to detect amyloid deposits in the brain, this imaging method is expensive and not widely available. Houston-based Alzeca hopes to bring amyloid-screening capability to MRI scanners, which are much more common.

Suggested Articles

The FDA has cleared Drawbridge Health’s blood collection device designed to help monitor long-term blood sugar levels in people with diabetes.

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

FierceMedTech Fierce 15 winner 10x Genomics announced its plans for a $100 million IPO, on the Nasdaq using the symbol TXG.